A nature-based solution for regulating the inflammatory phase of diabetic wound healing using a cold atmospheric plasma
Source abstract
Abstract
Diabetes is an inflammatory disease that usually causes chronic wounds for which no satisfactory therapies currently exist. Here we report a physical approach using a cold atmospheric plasma (CAP) to target diabetic wounds locally for regulating the inflammatory phase of the wounds. In this paper, a comprehensive analysis of inflammatory factors combined with physical investigations of the helium plasma jet characteristics is conducted. The physical and biological safety and clinical application prospects of the CAP jet for the human body are also analyzed. The results demonstrate for the first time that CAP therapy can stimulate the body's own inflammatory regulation function to achieve a normal state, rather than excessively interfere in a single target. This involves the inhibition of pro-inflammatory factors in the onset subphase and the promotion of anti-inflammatory factors in the subsequent resolution subphase. This research contributes to the development of highly effective and safe topical therapies to promote chronic wound healing.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Burn Injury Management and Outcomes · Plasma Applications and Diagnostics · Dermatologic Treatments and Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 204510.1016/j.diabres.2021.109119 ↗
2. Metabolic consequences of obesity and type 2 diabetes: Balancing genes and environment for personalized care10.1016/j.cell.2021.02.012 ↗
3. Diabetes mellitus and the β cell: The last ten years10.1016/j.cell.2012.02.010 ↗
4. The integrative biology of type 2 diabetes10.1038/s41586-019-1797-8 ↗
5. Exposing the exposures responsible for type 2 diabetes and obesity10.1126/science.aaf5094 ↗
6. Dissolved oxygen from microalgae-gel patch promotes chronic wound healing in diabetes10.1126/sciadv.aba4311 ↗
7. Management of a diabetic foot10.1001/jama.2017.11700 ↗
8. The diabetic foot: A global threat and a huge challenge for Greece
9. Type 2 diabetes as an inflammatory disease10.1038/nri2925 ↗
10. Macrophage-mediated inflammation in normal and diabetic wound healing10.4049/jimmunol.1700223 ↗
11. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes10.1038/ni.1935 ↗
12. TNF-α antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome10.1210/jc.2010-1170 ↗
13. Pharmacokinetic and pharmacodynamic characteristics of single-dose canakinumab in patients with type 2 diabetes mellitus10.1016/j.clinthera.2014.08.004 ↗
14. An overview of salsalate as a potential antidiabetic therapy10.1358/dot.2010.46.11.1534820 ↗
15. The impact of salsalate treatment on serum levels of advanced glycation end products in type 2 diabetes10.2337/dc13-1527 ↗
16. Anti-inflammatory agents in the treatment of diabetes and its vascular complications10.2337/dcS15-3015 ↗
17. Potential effects of nonsteroidal anti-inflammatory drugs in the prevention and treatment of type 2 diabetes mellitus10.1177/0897190016649551 ↗
18. Interleukin-targeted therapy for metabolic syndrome and type 2 diabetes10.1007/978-3-642-17214-4_11 ↗
19. A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance10.1007/s00125-012-2819-3 ↗
20. Effects of interleukin-1 beta inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: A phase IIb randomized, placebo-controlled trial10.1161/CIRCULATIONAHA.112.122556 ↗
21. Impact of interleukin-1beta antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: Results of secondary endpoints from a randomized, placebo-controlled trial10.1016/j.diabet.2013.07.003 ↗
22. New insights on the propagation of pulsed atmospheric plasma streams: From single jet to multi jet arrays10.1063/1.4934655 ↗
23. Numerical and experimental study of the dynamics of a μs helium plasma gun discharge with various amounts of N2 admixture10.1088/0963-0252/25/3/035002 ↗
24. Ionization wave propagation in an atmospheric pressure plasma multi-jet10.1088/1361-6595/ab4ab0 ↗
25. Plasma medicine: Possible applications in dermatology
26. Plasma in cancer treatment10.1016/j.cpme.2013.08.001 ↗
27. Cold atmospheric plasma for selectively ablating metastatic breast cancer cells
28. Cold plasma, a new hope in the field of virus inactivation10.1016/j.tibtech.2020.04.003 ↗
29. Plasma medicine: A field of applied redox biology
30. Eradication of methicillin-resistant Staphylococcus aureus biofilms by surface discharge plasmas with various working gases10.1088/1361-6463/ab32c9 ↗
31. Biological and medical applications of plasma-activated media, water and solutions10.1515/hsz-2018-0226 ↗
32. Blood coagulation and living tissue sterilization by floating-electrode dielectric barrier discharge in air10.1007/s11090-006-9024-4 ↗
33. Promotion of wound healing of genetic diabetic mice treated by a cold atmospheric plasma jet10.1109/TPS.2019.2928320 ↗
34. Plasma applications in medicine with a special focus on dermatology10.1111/j.1468-3083.2010.03702.x ↗
35. Plasma jet-induced tissue oxygenation: potentialities for new therapeutic strategies10.1088/0963-0252/23/1/012005 ↗
36. The repetitive use of non-thermal dielectric barrier discharge plasma boosts cutaneous microcirculatory effects10.1016/j.mvr.2016.02.008 ↗
37. Alleviation of chronic venous leg ulcers with a hand-held dielectric barrier discharge plasma generator (PlasmaDerm® VU-2010): Results of a monocentric, two-armed, open, prospective, randomized and controlled trial (NCT 01415622)10.1111/jdv.12490 ↗
38. Anti-bacterial action of plasma multi-jets in the context of chronic wound healing10.3390/app11209598 ↗
39. Combining biocompatible and biodegradable scaffolds and cold atmospheric plasma for chronic wound regeneration10.3390/ijms22179199 ↗
40. The efficacy and safety of cold atmospheric plasma as a novel therapy for diabetic wound in vitro and in vivo10.1111/iwj.13341 ↗
41. Cold atmospheric plasma as an effective method to treat diabetic foot ulcers: A randomized clinical trial10.1038/s41598-020-67232-x ↗
42. Anti-inflammatory effects of low temperature atmospheric plasma on acute pancreatitis induced by L-arginine in rats10.1063/5.0038350 ↗
43. Transdermal cold atmospheric plasma-mediated immune checkpoint blockade therapy10.1073/pnas.1917891117 ↗
44. Hydrogen peroxide: A central player in physical plasma-induced oxidative stress in human blood cells10.3109/10715762.2014.892937 ↗
45. A low cost, flexible atmospheric pressure plasma jet device with good antimicrobial efficiency10.1109/TRPMS.2023.3342709 ↗
46. Nitric oxide and superoxide in inflammation and immune regulation
47. The production efficiency of reactive oxygen and nitrogen species (RONS) of AC and pulse-DC plasma jet10.1109/TPS.2020.3030985 ↗
48. Production of active species in cold helium–air plasma jets10.1088/0963-0252/23/6/065014 ↗
49. Effect of dielectric barrier discharge plasma jet on bactericidal and human dermal fibroblasts adult cells: In vitro contaminated wound healing model10.1016/j.surfcoat.2020.126482 ↗
50. Cold atmospheric pressure plasma jet operated in Ar and He: From basic plasma properties to vacuum ultraviolet, electric field and safety thresholds measurements in plasma medicine10.3390/app12020644 ↗
51. Production of nitric/nitrous oxide by an atmospheric pressure plasma jet10.1088/0963-0252/25/2/025027 ↗
52. Temperature and NO density measurements by LIF and OES on an atmospheric pressure plasma jet
53. Blocking IL-1β induces a healing-associated wound macrophage phenotype and improves healing in type 2 diabetes10.2337/db12-1450 ↗
54. Effect of the function of polymorphonuclear leukocytes and interleukin-1 beta on wound healing in patients with diabetic foot infections10.1016/j.jinf.2006.05.004 ↗
55. Sustained inflammasome activity in macrophages impairs wound healing in type 2 diabetic humans and mice10.2337/db13-0927 ↗
56. The cytokine milieu of diabetic wounds10.2217/dmt.15.44 ↗
57. The role of inflammation in diabetes: Current concepts and future perspectives10.15420/ecr.2018.33.1 ↗
58. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes10.2337/dc09-0533 ↗
59. Adjunct methods of the standard diabetic foot ulceration therapy10.1155/2013/243568 ↗
60. Essential role of IL-12 in angiogenesis in type 2 diabetes10.1016/j.ajpath.2017.07.021 ↗
61. Diabetic wounds exhibit decreased Ym1 and arginase expression with increased expression of IL-17 and IL-2010.1089/wound.2015.0676 ↗
62. Silencing TNFα with lipidoid nanoparticles downregulates both TNFalpha and MCP-1 in an in vitro co-culture model of diabetic foot ulcers10.1016/j.actbio.2015.12.023 ↗
63. Abnormal cell responses and role of TNF-α in impaired diabetic wound healing10.1155/2013/754802 ↗
64. Possible effects of glimepiride beyond glycemic control in patients with type 2 diabetes: A preliminary report10.1186/1475-2840-13-15 ↗
65. Modulation of expression of the anti-inflammatory cytokines interleukin-13 and interleukin-10 by interleukin-310.1002/eji.1830260108 ↗
66. Anti-Inflammatory Cytokines10.1378/chest.117.4.1162 ↗
67. Immunological goings-on in visceral adipose tissue10.1016/j.cmet.2013.05.008 ↗
68. Role of pro- and anti-inflammatory phenomena in the physiopathology of type 2 diabetes and obesity10.4331/wjbc.v8.i2.120 ↗
69. Resolution of inflammation: An integrated view10.1002/emmm.201202382 ↗
70. Topical insulin application accelerates diabetic wound healing by promoting anti-inflammatory macrophage polarization
71. Much more than M1 and M2 macrophages, there are also CD169+ and TCR+ macrophages
72. IL-17–mediated M1/M2 macrophage alteration contributes to pathogenesis of bisphosphonate-related osteonecrosis of the jaws10.1158/1078-0432.CCR-13-0042 ↗
73. IL-37 suppresses the sustained hepatic IFN-γ/TNF-α production and T cell-dependent liver injury10.1016/j.intimp.2019.01.037 ↗
74. The role of macrophages in acute and chronic wound healing and interventions to promote pro-wound healing phenotypes10.3389/fphys.2018.00419 ↗
75. Wound healing essentials: Let there be oxygen10.1111/j.1524-475X.2008.00436.x ↗
76. Nitric oxide therapy for diabetic wound healing10.1002/adhm.201801210 ↗
77. Role of nitric oxide in inflammatory diseases10.1007/s10787-007-0013-x ↗
78. Nitric oxide enhances experimental wound healing in diabetes10.1046/j.1365-2168.2002.02263.x ↗
79. Treatment of chronic nonhealing leg ulceration with gaseous nitric oxide: A case study10.1177/120347540400800406 ↗
80. Gaseous nitric oxide exhibits minimal effect on skin fibroblast extracellular matrix gene expression and immune cell viability10.1042/CBI20100420 ↗
81. Efficacy of gaseous nitric oxide in the treatment of skin and soft tissue infections10.1111/j.1524-475X.2007.00239.x ↗
82. Nitric oxide prevents aortic neointimal hyperplasia by controlling macrophage polarization10.1161/ATVBAHA.114.303866 ↗
83. Chronic inflammatory diseases are stimulated by current lifestyle: how diet, stress levels and medication prevent our body from recover
84. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis10.1136/ard.2009.127225 ↗
85. Effect of cold atmospheric plasma therapy vs standard therapy placebo on wound healing in patients with diabetic foot ulcers: a randomized clinical trial10.1001/jamanetworkopen.2020.10411 ↗
86. The evaluation of efficacy of atmospheric pressure plasma in diabetic ulcers healing: A randomized clinical trial10.1111/dth.15169 ↗
87. Beneficial effects of cold atmospheric plasma on inflammatory phase of diabetic foot ulcers; a randomized clinical trial10.1007/s40200-020-00577-2 ↗
88. Enhanced growth factor expression in chronic diabetic wounds treated by cold atmospheric plasma10.1111/dme.14787 ↗
89. On the electrical safety of dielectric elastomer actuators in proximity to the human body10.1088/1361-665X/aa89b1 ↗
90. Characteristics of portable air floating-electrode dielectric-barrier-discharge plasmas used for biomedicine10.1007/s11090-023-10384-1 ↗
91. Mimicking of human body electrical characteristic for easier translation of plasma biomedical studies to clinical applications10.1109/TRPMS.2019.2936667 ↗
92. Basic principles of thermal dosimetry and thermal thresholds for tissue damage from hyperthermia10.1080/0265673031000119006 ↗
93. Atmospheric pressure plasma jet for medical therapy: plasma parameters and risk estimation10.1002/ctpp.200910067 ↗
94. Basic requirements for plasma sources in medicine10.1051/epjap/2011100452 ↗
95. Inhaled nitric oxide and pulmonary vasoreactivity10.1023/A:1011468005527 ↗
96. Foundations of plasmas for medical applications10.1088/1361-6595/ac604f ↗
97. A novel method for estimating the dosage of cold atmospheric plasmas in plasma medical applications
98. The application of cold atmospheric plasma in medicine: The potential role of nitric oxide in plasma-induced effects10.1016/j.cpme.2016.05.001 ↗
99. Biphasic effect of exogenous nitric oxide on proliferation and differentiation in skin derived keratinocytes but not fibroblasts10.1046/j.1523-1747.1998.00268.x ↗
100. Low-dose non-thermal atmospheric plasma promotes the proliferation and migration of human normal skin cells10.3390/app13052866 ↗